University of Vermont

College of Medicine

Vermont Lung Center

Clinical Trials

 

Every medicine you take was at one time considered an investigational drug. Dozens, sometimes hundreds, of volunteers test the safety and efficacy of new medicines before the drug comes on the market. As a research volunteer, you become an important part of a process that may help people improve their medical condition. The Vermont Lung Center is involved in several studies at all times. At the Vermont Lung Center, we are running several studies in Asthma, Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis, Cystic Fibrosis, and studies conducted in the Intensive Care Unit, of The University of Vermont Medical Center. Some may involve investigational drugs, others may be looking at the physiology of a certain condition. Before any clinical study gets underway, it must first be approved by the Institutional Review Board at the University of Vermont. The IRB is a multi-disciplinary group of professionals who review study protocols and any materials that will be used to recruit subjects.

Please find our current studies listed below. If you would like more information about clinical trials or participation in a clinical trial at the VLC, please call the Clinical Trials Office at (802) 847-2193. Vermont Lung Center Clinical Offices are located at 792 College Parkway, Medical Office Building, Suite 305, Colchester, VT  05446

 

Asthma Clinical Studies

Idiopathic Pulmonary Fibrosis Studies

Chronic Obstructive Pulmonary Disease Studies

Cystic Fibrosis Studies

Studies Conducted in the Intensive Care Unit

Cancer Survivor Studies

Pulmonary Hypertension Studies

Asthma

 

Status: Active - Recruiting
Asthma Patient Registry (APR)
Primary Invesitgator: Charles Irvin, Ph.D., Director, Vermont Lung Center
Coordinator: Kathleen Dwinell
Who: people with a physician diagnosis of asthma
What: 1 visit lasting approximately 30 minutes
Compensation: None
Status: Active - Recruiting
Study of Changes in Allergic Inflammation and Airway Remodeling During Bariatric Surgery
Primary Investigator: Anne Dixon, M.D.
Coordinator: Meena Subramanian
Who: Asthmatics ages 18 yrs. and older having bariatric surgery 
What: 2 visits
Compensation: $25 per visit
Status: Active - Recruiting
Epithelial Duox1, IL-33, and Allergic Inflammation
Primary Invesitgator: Anne Dixon, M.D.
Coordinator: Meena Subramanian
Who: Healthy Volunteers ages 18-65 yrs.
What: 1 visit
Compensation: $50
Status: Active - Recruiting
PFIZER - Biomarkers In Stable and Un-Stable Asthma
Primary Invesitgator: Anne Dixon, M.D.
Coordinator: Meena Subramanian
Who: Asthmatics using Advair or Symbicort ages 15-70 yrs.
What: 3 visits
Compensation: $300
   
Status: Active - Recruiting
Endotyping Asthma Phenotypes
Primary Invesitgator: Anne Dixon, M.D.
Coordinator: Meena Subramanian
Who: Asthmatics ages 18-65 yrs. with a BMI greater than 30
What: 1 visit
Compensation: up to $200

 

Status: Active - Recruiting
Soluble Interleukin - 6 Receptor Production in Asthma
Primary Invesitgator: Mercedes Rincon Ph.D.
Coordinator: Meena Subramanian
Who: Asthmatics Who have well controlled asthma and asthmatics with acute exacerbations ages 15-70 yrs.
What: 2-3 visits
Compensation: up to $150

Status: Active - Recruiting
NAC: Effects Of BMI On Allergic Responses
Primary Invesitgator: Anne Dixon, M.D.
Coordinator: Meena Subramanian
Who: Asthmatics and Healthy 18-60 yrs.
What: 2-3 Visits
Compensation: up to $150

Status: Active - Recruiting
UVM MG: Airway Compliance In Relation To BMI In Asthma
Primary Invesitgator: Anne Dixon, M.D.
Coordinator: Meena Subramanian
Who: Asthmatics and Healthy Subjects 35-55 yrs.
What: 3-4 Visits
Compensation: up to $300

 

Idiopathic Pulmonary Fibrosis (IPF)

Status: Active - Recruiting
RIFF: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Idiopathic Pulmonary  Fibrosis
Primary Invesitgator: Yolanda Mageto, M.D., MPH
Coordinator: Stephanie Burns
Who: People age 40 yrs. and over, with a diagnosis of IPF
What: Up to 34 visits over a 2 year period
Compensation: Reimbursement for travel over 100 miles

 

Status: Active - Recruiting
Fibrogen - 067: A Phase 2, Randomized, Double-Blind, placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients with Idiopathic Pulmonary Fibrosis
Primary Invesitgator: Yolanda Mageto, M.D., MPH
Coordinator: Stephanie Burns
Who: People age 40-80 yrs. inclusive with a diagnosis of IPF
What: Up to 38 visits over a 2 year period
Compensation: up to $3,800

 

Status: Active - Recruiting
BMS: Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis.  A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Efficacy of BMS-986020 in subjects with Idiopathic Pulmonary Fibrosis
Primary Invesitgator: Yolanda Mageto, M.D., MPH
Coordinator: Stephanie Burns
Who: People ages 40 yrs. and over, with a diagnosis of IPF
What: Up 14 visits for a total of 30 weeks
Compensation: up to $1,025 - $1,275

 

Chronic Obstructive Pulmonary Disease (COPD)

 

Status: Active - Recruiting
VHIP: The Effect of Pulmonary Rehabilitation on Ventilation Heterogeneity in Patients with COPD
Primary Invesitgator: David Kaminsky, M.D.
Coordinator: Stephanie Burns
Who: Patients enrolled in the UVM Medical Pulmonary Rehab Program
What: 2 visits one hour each
 
Status: Active - Recruiting
EMPROVE: A Prospective, Randomized, Controlled, Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the IBV Valve System for the Single Lobe Treatment of Severe Emphysema
Primary Invesitgator: C. Matthew Kinsey, M.D.
Coordinator: Sara Ardren
Who: Patients diagnosed with severe Emphysema
What: 7 visits over 12 weeks
 
Status: Active - Recruiting
Voucher-based incentives to promote smoking abstinence among patients with chronic obstructive pulmonary disease
Primary Invesitgator: Stacey Sigmon, Ph.D.
Co-Investigators: Anne Dixon, M.D., Charlotte Teneback, M.D.
Coordinator: Mollie Patrick
Who: Smokers who are over age 35 yrs. with a diagnosis of COPD
What: 2-week study with brief daily visits for monitoring smoking status
Compensation: Up to $587.50

 

Cystic Fibrosis

 

Status: Active - Recruiting
Serial Microbiome - Comparative Evaluation of Bacterial Diversity and Richness in the Cystic Fibrosis Lung In Patients Who Use Cycled Every Other Month Tobramycin Inhalation Powder (TIP, TOBI Podhaler) or continuous Alternating Therapy with Tobramycin Inhalation Powder (TIP, TOBI Podhaler) and Colistmethate (Colistin, Coly-Mycin M)
Primary Invesitgators: Charlotte Teneback, M.D.; Laurie Leclair, M.D.; Thomas Lahiri, M.D.; Lily Sender, PA-C
Coordinator: Rose Bergeron
Who: Volunteers ages 12 yrs. and over diagnosed with Cystic Fibrosis
What: 7 visits over 6 months
Compensation: $50 per visit

 

Cancer Survivor Studies

 

Status: Active - Recruiting
Predictors of Dyspnea/Fatigue Syndrome in Breast Cancer Survivors Before and After an Exercise Intervention
Study Description: The purpose of this study is to determine why fatigue and shortness of breath are such common side effects of cancer therapies and how fatigue and shortness of breath symptoms change after an exercise program.
Primary Invesitgators: Benjamin Suratt, MD; Kim Dittus, MD, PhD; Deboarah Rubin, MD; David Kaminsky, MD; Susan Lakoski, MD, MS
Coordinator: Karen Wilson, CCRP
Who: Adult breast cancer patients initiating chemotherapy for the first time
What: Enrolled participants will be randomized to engage in supervised exercise either during the time they are receiving chemotherapy or after they have completed chemotherapy.
Compensation: $0, pedometer

 

Pulmonary Arterial Hypertension

 

Status: Active - Recruiting
Changes in the Diffusion Capacity for Carbon Monoxide (DLCO) in Response to Vasodilator Therapy in Patients with Pulmonary Arterial Hypertension
Primary Invesitgator: Sanjiva Lutchmedial, M.D.
Coordinator: Stephanie Burns
Who: Patients with Pulmonary Arterial Hypertension
What: 3 visits
Compensation: Up to $150

Last modified June 03 2015 10:44 AM